Background
In the central nervous system (CNS), abnormal protein aggregation, autoimmunity, and infection can lead to neurodegenerative conditions, such as amyotrophic lateral sclerosis (ALS) [
1], Alzheimer’s disease (AD) [
2], Parkinson’s disease (PD) [
3], and primary progressive multiple sclerosis (PPMS) [
4]. Inflammation within the CNS, where reactive glia shift toward a proinflammatory phenotype, is common to these neurodegenerative diseases. As the resident immune cells in the CNS, glial cells release cytokines, chemokines, as well as potentially neurotoxic substances including excess levels of glutamate, nitric oxide, and arachidonic acid [
5] during disease states. Cytokines, especially TNF-α, are typically elevated during neurodegenerative disease states and further promote CNS inflammation [
6]. TNF-α is known to exert both homeostatic and pathophysiological roles in the central nervous system by regulating immunologic and metabolic states of astrocytes, the main glial cell type in the CNS [
7,
8].
Glutamate metabolism is one of the major metabolic pathways in the CNS. Glutaminase (GA; EC 3.5.1.2), an enzyme localized in the inner membrane of the mitochondria, is a rate-limiting enzyme in glutamate metabolism that catalyzes the conversion of glutamine to glutamate and ammonia [
9]. Glutaminase is abundantly expressed in the brain. The main cell types for glutaminase expression include neurons, but microglia, macrophages, and astrocytes are also known to express glutaminase [
10]. The mammalian GA family members are encoded by two paralogous genes,
Gls and
Gls2, presumably derived from a common ancestral gene by duplication and divergent evolution [
11]. Furthermore, two glutaminase (GLS) allozymes, glutaminase C (GAC) and kidney type glutaminase (KGA), are from two different transcripts and both are expressed in the brain. Research on GLS has long been focused on neurotoxicity and cancer. Recent evidence indicates that GLS might also be important in intercellular communication through extracellular vesicles [
12‐
14].
Extracellular vesicles (EVs) are membrane-contained vesicles that include exosomes, microvesicles, and apoptotic bodies [
15]. EVs can be released into interstitial fluid, cerebrospinal fluid (CSF) [
16], circulating blood [
17], urine [
18], lymph [
19], and glandular secretions, asserting functions to nearby or distant cells [
20]. Almost all body cells release EVs that fuse with target cells, by which proteins, lipids, or nucleic acids are transferred from cell to cell. Therefore, EVs are important mediators of cell-to-cell communication [
21]. EVs are abundant in the CNS and are thought to facilitate the intercellular communication, maintenance of myelination, synaptic plasticity, antigen presentation, and tropic support of neurons [
22,
23]. Therefore, it is of great significance to study the mechanism of EV release in order to understand the development and progression of CNS inflammation.
To determine the mechanism of EV release during neuroinflammation, we used TNF-α to stimulate primary mouse astrocytes. TNF-α induced the increased release of EVs and elevated protein levels of GLS in mouse astrocytes. Furthermore, TNF-α induced the generation of reactive oxygen species (ROS) in astrocytes through GLS. Treatment with either a glutaminase inhibitor, an antioxidant N-acetyl-l-cysteine, or using astrocytes that had genetic knockout of glutaminase (Gls−/−) reduced TNF-α-mediated EV release, suggesting that glutaminase is required for EV release in astrocytes during neuroinflammation. Understanding the mechanism of EV release in astrocytes during neuroinflammation is important in identifying novel therapeutic targets in the relevant neurological diseases.
Methods
Animals and reagents
C57BL/6J mice were housed and maintained in the Comparative Medicine Facility of the Tongji University School of Medicine (Shanghai, China). All procedures were conducted in accordance with the protocols approved by the Institutional Animal Care and Use Committee at the Tongji University School of Medicine. Postnatal (P1 to P2) brain tissues were used for mouse astrocyte cultures. Gls knock in mouse embryonic stem (ES) cells were obtained from the Knockout Mouse Project (KOMP) Repository (CA, USA). Recombinant mouse TNF-α and IL-1β were obtained from R&D Systems. N-Acetyl-l-cysteine (NAC, A7250), 6-Diazo-5-oxo-l-norleucine (L-DON, D2141), BPTES (SML0601), and GW4869 (D1692) were obtained from Sigma-Aldrich.
Isolation and culture of primary mouse astrocytes
Cortices of C57BL/6J mice were dissected and mechanically dissociated using forceps to remove the membranes and large blood vessels. Brain tissues were digested by Trypsin-EDTA (Life Technologies) and then plated on cell culture flasks in Dulbecco’s modified Eagle medium Nutrient Mixture F-12 (DMEM/F-12). Culture medium was supplemented with FBS (10% v/v) and penicillin/streptomycin (1% v/v). Cultures were maintained in a humidified chamber (37 °C, 5% CO2 incubator). After 7 to 10 days, the astrocytes were harvested by trypsinization.
Isolation of EVs
The method for the isolation of extracellular vesicles has been described previously [
24]. EVs were isolated from the serum-free culture of mouse astrocytes through differential centrifugation. Briefly, the supernatants were first centrifuged at 300 ×
g for 10 min to remove free cells, at 3000 ×
g for 20 min to remove cellular debris, and then 10,000 ×
g for 30 min to remove intracellular organelles. Lastly, EVs were collected by ultracentrifugation at 100,000 ×
g for 2 h at 4 °C. To prepare EVs for western blot, the EVs pellets were lysed in M-PER mammalian protein extraction reagent (Thermo Scientific, Pittsburgh, PA).
Dynamic light scattering
Extracellular vesicles were characterized at 25 °C using Nano ZS90 (Malvern Instruments, UK). Eighty microliter samples were loaded into a microcuvette (ZEN0118, Malvern Instruments, UK) for measurement.
Nanoparticle tracking analysis (NTA)
The size and number of extracellular vesicles were assessed with NanoSight NS300 system (Malvern Instruments, UK). Astrocytes were cultured in 6-cm culture dishes. At 24 h after medium change, EVs were isolated from normalized volumes of serum-free culture supernatants through differential centrifugation and resuspended with 150 μl PBS. The supernatant was diluted at 1:100 in PBS, and 1 ml solution was used for NanoSight analysis.
Scanning electron microscopy (SEM)
Mouse astrocytes were grown on a glass coverslip, fixed with 2.5% glutaraldehyde, and washed three times with PBS. The cells were then dehydrated in a series of increasing ethanol concentrations and transferred for critical drying. After coating with platinum/palladium using a sputter coater, the sample was imaged with a scanning electron microscope (S-3400, Hitachi).
Transmission electron microscopy (TEM)
EVs were negatively stained and then spread on the copper grids. The droplets of EVs were removed with filter paper and air-dried at room temperature. Images were obtained using transmission electron microscopy (JEM-1230, JEOL Ltd.).
Western Blot
Cells or EV pellets were lysed in M-PER mammalian protein extraction reagent (Thermo Scientific). Proteins from lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). After electrophoretic transfer to polyvinyldifluoridene (PVDF) membranes (Millipore, Billerica, MA, USA), proteins were treated with purified primary antibodies for glutaminase (1:1000; Abcam), GFAP (1:1000; Cell Signaling Technologies), β-actin (1:5000; Sigma Aldrich), flotillin-2 (1:5000; BD biosciences), and ALG-2 interacting protein (Alix) (1:1000; Cell Signaling Technologies) overnight at 4 °C followed by a horseradish peroxidase-linked secondary anti-rabbit or anti-mouse antibody (1: 5000; Icllab). Antigen–antibody complexes were visualized by Pierce ECL Western Blotting Substrate. Mitochondrial protein was isolated by the Mitochondria Isolation Kit for Cultured Cells (ab110171, Abcam). ATP5A (1:1000; Abcam) was used as a mitochondrial marker to indicate that there is no mitochondria contamination in the cytosol.
Immunocytochemistry
Mouse astrocytes cultured on cover glasses were fixed with 4% PFA, rinsed with PBS, and then blocked by 2% BSA in PBS. Cells were incubated overnight at 4 °C with primary antibodies anti-GFAP (1:1000; Abcam). Cover glasses were washed and incubated for 1 h at room temperature with secondary antibodies including anti-mouse IgG (coupled with Alexa Fluor 488, Life Technologies). Nuclear DNA was stained with DAPI. Cover glasses were mounted on glass slides with mounting buffer (Sigma-Aldrich). Morphological changes were visualized by a Zeiss 710 confocal laser scanning microscope.
ROS measurement
ROS measurement was assayed by dichloro-dihydro-fluorescein diacetate (DCFH-DA). Mouse astrocytes were incubated in 10 μM DCFH-DA (50101, YEASEN) for 30 min at 37 °C, 5% CO2 and then were washed with PBS. The ROS were determined using conventional fluorescence microscopy (ZEISS).
Intracellular and extracellular glutamate analysis
Intracellular glutamate detection was performed with the Amplex Red Glutamic Acid/Glutamate Oxidase Assay Kit from Invitrogen following manufacturer’s procedure. High performance liquid chromatography (HPLC) analysis for extracellular glutamate was performed as previously described [
25].
Cell viability measurement
Briefly, mouse astrocytes were treated with TNF-α for 24 h, the cell viability was assayed by cell viability assay kit (Promega, G7570). The luminescent signal recording from the reaction was as the standard of cell viability.
Statistical analyses
Data were evaluated statistically by the analysis of variance (ANOVA), followed by Tukey’s test for multiple comparisons. Data were shown as mean ± SD. *, **, and *** denote p < 0.05, p < 0.01, and p < 0.001 in comparison to control, respectively. #, ##, and ### denote p < 0.05, p < 0.01, and p < 0.001 in comparison to TNF-α-treated groups, respectively.
Discussion
In this study, our results present three important new findings regarding EV release. First, TNF-α treatment significantly promoted the release of EVs in mouse astrocytes. Second, TNF-α upregulated the protein level of glutaminase and pretreatment with a glutaminase inhibitor blocked TNF-α-mediated generation of ROS in astrocytes. Last, the TNF-α-mediated increased release of EVs can be inhibited by either the glutaminase inhibitor, antioxidant NAC, or genetic knockout of glutaminase. These observations suggest that GLS may contribute to EV release in mouse astrocytes.
EVs are associated with the message delivery of the nervous system and may involve in the pathogenesis of many neuroinflammatory disorders, both infectious and neurodegenerative [
36]. However, the mechanism underlying formation and secretion of EVs is still unclear. EVs are modulated in different cell types by various environmental changes, such as ligand encounter or stress conditions, and could be one of the means used by tissues to adapt to these changes [
37]. There have been reports showing that EV release is modulated by induction of ROS [
32‐
34], inflammation and ATP [
38], calcium [
39], and acid sphingomyelinase [
40]. The important observation reported here is that TNF-α increased ROS generation, and that this can be blocked by GLS inhibitors. Glutaminase is usually located in the mitochondria, and our previous study showed that ROS could cause the location change in macrophage [
28]. These findings suggest that GLS and ROS can influence each other. More importantly, TNF-α-mediated increased release of EVs can be inhibited by both antioxidant NAC and GLS inhibitors. ROS activates various stress pathways, including proapoptotic p38, p53, and SAPK/JNK MAPK pathways and inflammatory NF-ĸB pathway, and promotes increased shedding of EVs, antiangionenic factors, and inflammatory cytokines [
41,
42].
Glutaminase is one of the key enzymes in cell metabolism. We have previously studied the effects of neuron, macrophage, and microglia GLS in brain injury, infection, and inflammation [
5,
11,
24,
25,
29,
43]. Recently, we found that HIV-1 infection and immune activation increase EV release from macrophages and microglia [
24]. Interestingly, GAC, an isoform of GLS, is released into the extracellular fluid primarily via EVs and it then induces neurotoxicity. Others found that larger vesicles (microvesicles) are sensitive to glutamine inhibition, as the introduction of a glutaminase inhibitor significantly disrupted their production in cancer cells [
12]. However, due to the limitation of DLS technology, it could not analyze the number, concentration, and particle sizes of EVs. The work described here showed the EV releasing role of TNF-α by a mouse astrocyte model. The concentrations and diameters of EVs were detected by NTA, which provides accurate measurements. Our current studies found that TNF-α increased EV release in mouse astrocytes. Furthermore, the analysis of glutaminase isoforms revealed that TNF-α upregulated GAC expression in mouse astrocytes. Inhibition of GLS and ROS both could decrease the EV release which was mediated by TNF-α. We also investigated the level of EVs in Gls−/− mouse astrocytes. The concentration of EVs in Gls−/− astrocytes was ten-fold lower than wild type astrocytes, and the level of EVs in Gls−/− astrocytes did not change after TNF-α treatment.
Astrocytes use gliotransmitters to modulate neuronal function and plasticity. Recently, others discovered a fundamentally different form of long-term potentiation (LTP) that is induced by glial cell activation and mediated by diffusible, extracellular messengers, including D-serine and tumor necrosisfactor (TNF), and were spread widely in nociceptive pathways [
44]. Astrocyte-derived EVs are heterogeneous in their composition and have been ascribed as having beneficial and detrimental functions, and they promise to be an exciting area of exploration. However, changes in the contents of EVs and its effect on other cells in the nervous system remain to be studied. Astrocyte-derived EVs have been implicated in the propagation of pathogenic proteins in neurodegenerative disorders [
45], and they also can mediate neuroprotection [
46]. In cancer, people have found that astrocyte-derived EVs induce PTEN suppression to foster brain metastasis, these findings highlighted an important plastic and tissue-dependent nature of metastatic tumor cells and a bi-directional co-evolutionary view of “seed and soil” hypothesis [
47]. The cargo and the secretion mechanism of astrocyte-derived EVs may open the doors to a better understanding of how astrocytes impact on neuronal functions, and it may also provide us with new tools to compensate for cellular malfunctions under pathological conditions. Addressing this question poses one important challenge, which requires the development of techniques that induce EV secretion in vivo. Another major challenge to us is uncovering the relationship between glutaminase and EV release, but specifically packaged cargo and physiological function of EVs in vivo.
In summary, we have identified glutaminase as an important player in mediating EV over-release during inflammatory cytokines stimulation. EVs in inflammatory stress may be associated with the occurrence and development of the disease and cellular immune regulation. Uncovering the important role of glutaminase in inflammation-induced EV release, GLS may provide a potentially pathological mechanism in neuroinflammation, and a possible therapeutic target of inflammatory brain diseases.
Acknowledgements
We thank Dr. Chao Lin (Tongji University, Shanghai, China) for the assistance with the DLS. We thank Dr. Bin Li (Shanghai Institute of Applied Physics, Chinese Academy of Science) for providing Nanosight NS300. We thank Dr. Matthew SMitchell for editing the manuscript.